Ernst-Wilhelm Radüe

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

Richard A. Rudick, William H. Stuart, Peter A. Calabresi et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Peter A. Calabresi, Ernst-Wilhelm Radüe, Douglas S. Goodin et al. · The Lancet Neurology · 2014 · 815 citations

Disease Management, Relapsing-remitting Multiple Sclerosis, Disease Progression +7

Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis

Sergio E. Baranzini, Joanne Wang, Rachel A. Gibson et al. · Human Molecular Genetics · 2008 · 468 citations · Full text

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

Ludwig Kappos, Nicola De Stefano, Mark S. Freedman et al. · Multiple Sclerosis Journal · 2016 · 276 citations · Full text

Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging

Reza Rahmanzadeh, Po‐Jui Lu, Muhamed Baraković et al. · Brain · 2021 · 106 citations · Full text

Neurological Disorder, White Matter, Neurite Density Index +18